Sodium Pentaborate–Curcumin–Piperine Formulation to Limit HCC Drug Resistance

Solution Overview

Problem

Current treatments for hepatocellular carcinoma, such as liver transplantation, surgical resection, chemotherapy, and radiation, are limited in efficacy and often lead to drug resistance, with existing drugs like Sorafenib, Bevacizumab, and Regorafenib showing resistance issues and poor survival benefits.

Innovation Solution

A pharmaceutical formulation combining sodium pentaborate, curcumin, and piperine is developed to synergistically target different cellular pathways, preventing drug resistance and reducing cytotoxic effects by administering lower doses than optimal single-drug doses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (liver transplantation, surgical resection, chemotherapy, radiation) are used for hepatocellular carcinoma, then early-stage tumors can be treated, but recurrence rates exceed 80% and treatment is limited to small percentage of patients

Engineering Contradiction:

Improvetreatment efficacyVSAvoidapplicability to patients

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines multiple anti-cancer agents (sodium pentaborate, curcumin, and piperine) into a single pharmaceutical formulation. This combination approach targets multiple cellular pathways simultaneously, preventing drug resistance while treating hepatocellular carcinoma. The synergistic effect of the combined agents enhances treatment efficacy beyond what single agents can achieve alone.

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If existing chemotherapy drugs (Sorafenib, Bevacizumab, Regorafenib) are administered, then cancer treatment is provided, but drug resistance develops and survival benefits are poor

Engineering Contradiction:

Improvetreatment efficacyVSAvoiddrug resistance development

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent combines multiple anti-cancer agents (sodium pentaborate, curcumin, and piperine) into a single pharmaceutical formulation. This combination approach targets multiple cellular pathways simultaneously, preventing drug resistance while treating hepatocellular carcinoma. The synergistic effect of the combined agents enhances treatment efficacy beyond what single agents can achieve alone.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent alters the chemical parameters by selecting specific compounds with different mechanisms of action: sodium pentaborate (boron derivative), curcumin (polyphenol), and piperine (alkaloid). These parameter changes in drug selection prevent resistance development by engaging multiple cellular targets with structurally and mechanistically diverse agents.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If high doses of single anti-cancer agents are administered to achieve optimal efficacy, then cancer cell killing is maximized, but cytotoxic effects increase

Engineering Contradiction:

Improveanti-cancer efficacyVSAvoidcytotoxic effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines multiple anti-cancer agents (sodium pentaborate, curcumin, and piperine) into a single pharmaceutical formulation. This combination approach targets multiple cellular pathways simultaneously, preventing drug resistance while treating hepatocellular carcinoma. The synergistic effect of the combined agents enhances treatment efficacy beyond what single agents can achieve alone.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20250228890A1Anti-cancer formulation comprising sodium pentaborate, curcumin and piperine for use in the treatment of hepatocellular carcinoma

Publication Date: 2025.07.17 YEDITEPE UNIVERSITESI

AI summary

The present invention relates to a formulation together comprising sodium pentaborate, curcumin, and piperine as active substances and to use thereof in the treatment of hepatocellular carcinoma.